Stock Value
Competitors
| Ticker | Price | Forecast 1Y | Forecast 2Y | Market Cap | Div Yld | Growth Rate |
|---|---|---|---|---|---|---|
|
NYSE:LLY
Eli Lilly and
|
734.97 | -46.29% | -24.25% | 661,770.95 | 0.69% | 2.63% |
|
NYSE:MRK
Merck
|
127.51 | -7.42% | 6.15% | 322,986.42 | 2.4% | -19.03% |
|
NYSE:ABBV
AbbVie
|
163.79 | -21.82% | -11.49% | 290,014.27 | 3.86% | 7.03% |
|
LSE:AZN
AstraZeneca PLC
|
120.50 | 19.51% | 42.34% | 186,803.32 | 2.04% | 15.98% |
|
SWX:ROG
Roche Holding
|
217.30 | 36.77% | 53.45% | 175,193.12 | 4.48% | 0.43% |
|
NYSE:PFE
Pfizer
|
27.81 | 11.74% | 42.95% | 157,475.27 | 6.06% | -9.31% |
|
NasdaqGS:REGN
Regeneron Pharmaceuticals
|
957.00 | -27.73% | -21.57% | 105,447.53 | 0% | 13.9% |
|
NYSE:BMY
Bristol-Myers Squibb
|
43.99 | 61.89% | 72.23% | 89,172.13 | 5.49% | 13.54% |
|
SHSE:600276
Jiangsu Hengrui Medicine
|
46.16 | 36.14% | 73.21% | 293,511.12 | 0.43% | 1.61% |
|
SEHK:1093
CSPC Pharmaceutical Group
|
6.76 | 37.88% | 54.6% | 76,753.21 | 4.17% | 19.3% |
|
SEHK:1801
Innovent Biologics
|
40.90 | 0% | 0% | 62,067.62 | 0% | 0% |
|
SHSE:600196
Shanghai Fosun Pharmaceutical (Group)
|
23.67 | 95.66% | 189.87% | 56,484.21 | 1.14% | -2.01% |
|
SEHK:9926
Akeso
|
49.00 | 0% | 0% | 41,691.02 | 0% | -,262.86% |
|
SZSE:300003
Lepu Medical Technology (Beijing)
|
14.75 | 185.62% | 251.51% | 27,400.16 | 2.25% | 0.34% |
|
SEHK:1877
Shanghai Junshi Biosciences
|
12.34 | 0% | 0% | 27,513.36 | 0% | 0% |
|
SHSE:600062
China Resources Double-Crane Pharmaceutical
|
21.77 | 0% | 0% | 22,226.69 | 1.18% | 13.43% |
|
NasdaqGM:ZLAB
Zai Lab
|
16.25 | 0% | 0% | 1,559.74 | 0% | 0% |
|
SEHK:9969
InnoCare Pharma
|
5.35 | 0% | 0% | 9,404.27 | 0% | 0% |
|
SEHK:2696
Shanghai Henlius Biotech
|
16.60 | 0% | 0% | 8,869.84 | 0% | -,171.88% |
|
SEHK:9966
Alphamab Oncology
|
5.19 | 0% | 0% | 4,583.01 | 0% | 0% |
